Show simple item record

dc.contributor.authorZhang, Y
dc.contributor.authorJi, F
dc.contributor.authorHu, X
dc.contributor.authorCao, Y
dc.contributor.authorLatour, Jos M
dc.date.accessioned2017-07-06T07:07:32Z
dc.date.available2017-07-06T07:07:32Z
dc.date.issued2017-06-14
dc.identifier.issn1529-7535
dc.identifier.issn1947-3893
dc.identifier.urihttp://hdl.handle.net/10026.1/9595
dc.descriptionPublisher policy: author can archive post-print on institutional repository after 12 months embargo. Publisher's version/PDF cannot be used. Must include statement that it is not the final published version. Published source must be acknowledged with full citation. Must link to publisher version
dc.description.abstract

<jats:sec> <jats:title>Objectives:</jats:title> <jats:p>Studies have confirmed the safety of oropharyngeal administration of colostrum in very low birth weight infants. However, the effect of oropharyngeal administration of colostrum on immune system is inconclusive. This study aims to evaluate the effect of oropharyngeal administration of colostrum on secretory immunoglobulin A and lactoferrin in very low birth weight infants.</jats:p> </jats:sec> <jats:sec> <jats:title>Design:</jats:title> <jats:p>Randomized controlled trial.</jats:p> </jats:sec> <jats:sec> <jats:title>Setting:</jats:title> <jats:p>Forty-bedded neonatal ICU in a university children’s hospital in the People’s Republic of China.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients:</jats:title> <jats:p>Very low birth weight infants were allocated to the study group (<jats:italic toggle="yes">n</jats:italic> = 32) and control group (<jats:italic toggle="yes">n</jats:italic> = 32).</jats:p> </jats:sec> <jats:sec> <jats:title>Intervention:</jats:title> <jats:p>The intervention was oropharyngeal administration of 0.2 mL of their mother’s colostrum every 4 hours for 7 days. The control group received saline solution.</jats:p> </jats:sec> <jats:sec> <jats:title>Measurements and Main Results:</jats:title> <jats:p>Secretory immunoglobulin A and lactoferrin in urine and saliva were measured within 24 hours of life (baseline) and at 7 and 21 days. Primary outcomes were changes of secretory immunoglobulin A and lactoferrin in urine and saliva between baseline and at 7 and 21 days. Infant’s clinical data were also collected during hospitalization. Change from baseline in lactoferrin in saliva at 7 days (5.18 ± 7.07 vs –1.74 ± 4.67 µg/mL; <jats:italic toggle="yes">p</jats:italic> &lt; 0.001) and 21 days (5.31 ± 9.74 vs –1.17 ± 10.38 µg/mL; <jats:italic toggle="yes">p</jats:italic> = 0.02) shows statistic difference. No differences were found of lactoferrin in urine and also no differences of secretory immunoglobulin A in urine and saliva. There were also no differences between days to full enteral feeding, occurrence rate of clinical sepsis, proven sepsis, and necrotizing enterocolitis.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Oropharyngeal administration of colostrum can increases the level of lactoferrin in saliva in very low birth weight infants. No effect could be documented of secretory immunoglobulin A and lactoferrin in urine. Larger trials are needed to better describe the benefit of oropharyngeal administration of colostrum, if any, in very low birth weight infants.</jats:p> </jats:sec>

dc.format.extent1-1
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.subjectfeeding methods
dc.subjectimmunotherapy
dc.subjectinfection
dc.subjectneonatology
dc.subjectpremature infants
dc.titleOropharyngeal Colostrum Administration in Very Low Birth Weight Infants
dc.typejournal-article
dc.typeJournal Article
dc.typeRandomized Controlled Trial
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000408818800013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue9
plymouth.volume18
plymouth.publication-statusPublished
plymouth.journalPediatric Critical Care Medicine
dc.identifier.doi10.1097/PCC.0000000000001221
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/School of Nursing and Midwifery
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Health and Community
plymouth.organisational-group/Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR)
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeUnited States
dcterms.dateAccepted2017-04-05
dc.rights.embargodate2018-6-14
dc.identifier.eissn1947-3893
dc.rights.embargoperiod12 months
rioxxterms.versionofrecord10.1097/PCC.0000000000001221
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2017-06-14
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV